Author: OurCrowd

[CytoReason in The Times of Israel] Japanese pharmaceutical firm taps Israel’s CytoReason for AI drug development

CytoReason, an Israeli startup that uses artificial intelligence to build digital models of the human immune system and diseases to speed up drug development, said on Thursday that it was partnering with Japan’s Summit Pharmaceuticals International (SPI) to integrate its machine learning platform into the Japanese clinical drug discovery sector. Read...

Read More

[SaNOtize in Times of india] GMCH to host nasal spray trials to treat Covid-19 patients

ANAMA — Bahrain has authorized a clinical study to evaluate the use of Enovid nasal spray to treat individuals with COVID-19. The authorization by Bahrain’s National Health Regulatory Authority (NHRA) follows a medical study submitted by the relevant authorities at the Ministry of Health, which indicates their support for a clinical trial to take place in Bahrain. Enovid will be tested on volunteers who have already been diagnosed with COVID-19 and who are suffering from mild symptoms. Read more...

Read More